Denied its request for an injunction, Medtronic seeks royalties and interest on top of a $101 million patent win for NuVasive's infringing spinal implants.
The motion follows Medtronic's September win, when a California jury awarded the med-tech titan $101 million after deciding that San Diego-based NuVasive wilfully infringed on Medtronic's patents.
After Judge Michael Anello of the U.S. District Court for Southern California shut down Medtronic's request for a permanent injunction, the company responded by asking for a percentage of NuVasive's ongoing sales and requesting $19.8 million in interest on the verdict already granted.
"Anything less would reward NuVasive's ongoing infringement and would encourage NuVasive to continue to infringe rather than to develop its own technology," Medtronic argued in court documents. "NuVasive has the ability to pay these rates and should not be permitted to earn a substantial profit from its ongoing infringement."
Minneapolis, Minn.-based Medtronic wants 36% in royalties on 1 infringed patent, 11% on another and 7% on the 3rd, higher rates than the jury suggested.
NuVasive asked the court to refrain from setting rates to give the companies more time to negotiate on their own, or otherwise set royalties at 10% for the 1st patent, 3% for the 2nd and 2% for the 3rd, consistent with the jury's suggestion.
Intersect ENT enrolls the 1st patient in its PROGRESS study, aiming to expand the patient population...
Innovative needle design to enhance patient safety.
Medtronic taps Dr. Elizabeth Nabel, president of Brigham & Women's Faulkner Hospital in Boston,...
NxStage Medical wins FDA clearance to market its OneSite single needle dialysis technology for use...